Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abbott buys Vysis for $355mm

Executive Summary

In a deal that will greatly strengthen its molecular diagnostics product line, Abbott Laboratories acquired BP's genomics testing products unit Vysis Inc. for $30.50 per share, or about $355 million. Based on Vysis's average trading price, Abbott is paying a 39% premium for the shares.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Urine-based Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Includes Contract
    • Full Acquisition

Related Companies

UsernamePublicRestriction

Register